Lifecore Biomedical and clinical-stage innovator Indomo have announced a new development services agreement to push forward Indomo’s corticosteroid drug candidate, DT-001, designed for use with its intradermal self-injection device, the ClearPen.
The therapy targets inflammatory acne lesions, a condition affecting 50 million Americans each year.
This marks the second deal between the companies, following a prior agreement where Lifecore provided formulation and process optimization for DT-001. Under the new pact, Lifecore will produce and supply engineering and clinical batches of DT-001 to support studies aimed at advancing the therapy into Phase 2 clinical trials in 2026.
“We are thrilled to continue to grow our relationship with Indomo and support a customer that possesses such high-quality leadership and ambitious plans for innovation. This work with Indomo highlights the success of our continued efforts to expand beyond our traditional focus in ophthalmic therapies, while also enhancing our leadership in rapidly growing autoinjector technologies,” said Paul Josephs, president and CEO of Lifecore.
“We are excited to get to work on producing engineering and clinical batches for Indomo and supporting the company’s plans to move into Phase 2 studies.”
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation, enabling consistent at-home dosing.
Intralesional injections of triamcinolone acetonide, backed by more than 50 years of clinical use, are recognized by the American Academy of Dermatology as a first-line treatment for acne. Yet despite the high prevalence of acne, only one million Americans regularly receive corticosteroid injections, largely due to limited access: there are just 12,000 dermatologists in the U.
S, or one for every 28,000 people. Indomo’s at-home approach aims to bridge that gap.
“As we progress toward Phase 2 studies, it was critical for Indomo to partner with a CDMO that combines technical excellence with a forward-looking approach to innovation.
"Lifecore’s expanding leadership in injectable therapeutics and their commitment to speed and high-quality execution position them as a key partner in advancing our therapeutic pipeline. We are excited to deepen this collaboration as we move into the next phase of development,” said Rick Bente, CEO of Indomo.
